Evidence map›Paper›PMID 40542967›Full record

ArticleInternational urology and nephrology2026

Robotic partial nephrectomy to treat large (T2) cystic renal cell carcinoma: a multi-institutional analysis (ROSULA Collaborative Group).

Lin Zhao, Xiaolei Shi, Fei Guo, Jiaying Miao, Chao Zhi, Guangan Xiao, Francesco Porpiglia, Riccardo Autorino, Umberto Capitanio, Robert Uzzo and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lin Zhao *Department of Urology, Changhai Hospital, Naval Medical Univesity, Shanghai, China.
Xiaolei Shi *Department of Urology, Changhai Hospital, Naval Medical Univesity, Shanghai, China.
Fei Guo *Department of Urology, Changhai Hospital, Naval Medical Univesity, Shanghai, China.
Jiaying MiaoDepartment of Urology, Changhai Hospital, Naval Medical Univesity, Shanghai, China.
Chao ZhiDepartment of Urology, Changhai Hospital, Naval Medical Univesity, Shanghai, China.
Guangan XiaoDepartment of Urology, Changhai Hospital, Naval Medical Univesity, Shanghai, China.
Francesco PorpigliaDepartment of Urology, School of Medicine, University of Turin-San Luigi Gonzaga Hospital, Turin, Italy.
Riccardo AutorinoDepartment of Urology, Rush University Medical Center, Chicago, USA.
Umberto CapitanioUnit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Robert UzzoInstitution Fox Chase Cancer Center, Philadelphia, USA.
Chandru SundaramDepartment of Urology, Indiana University, Indianapolis, USA.
Alexandre MottrieDepartment of Urology, ORSI Academy, Melle, Belgium, OnzeLieveVrouw Hospital, Aalst, Belgium.
Sisto PerdonàDivision of Urology, IRCCS Pascale Foundation, Naples, Italy.
Daniel EunDepartment of Urology, Lewis Katz School of Medicine, Temple University Philadelphia, Philadelphia, USA.
Jihad KaoukGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Giuseppe SimoneDepartment of Urology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Ithaar H DerweeshDepartment of Urology, UC San Diego School of Medicine, La Jolla, San Diego, CA, USA.
Linhui WangDepartment of Urology, Changhai Hospital, Naval Medical Univesity, Shanghai, China.
Bo YangDepartment of Urology, Changhai Hospital, Naval Medical Univesity, Shanghai, China. yangbochanghai@126.com.
Chao ZhangDepartment of Urology, Changhai Hospital, Naval Medical Univesity, Shanghai, China. czhangurol@126.com.

Funding

National Natural Science Foundation of China 82203134Natural Science Foundation of Shanghai Grant No.21ZR1479000
6 · The paper itself

Abstract

purposeTo investigate the feasibility and safety of robot-assisted partial nephrectomy (RAPN) to treat large (T2) cystic renal-cell carcinoma.

methodsA multinational study was conducted worldwide. Patients with renal tumors larger than 7cm who underwent partial nephrectomy between December 2007 and July 2017 were recruited retrospectively. The patients were divided into solid tumor group (143 cases) and cystic tumor group (28 cases). Baseline parameters, tumor characteristics, perioperative variables, and pathological outcomes were collected.

resultsBetween cystic and solid tumors, no statistically significant differences were detected in age, gender, BMI, ASA score, clinical tumor size, laterality, or R.E.N.A.L nephrometry score. Operating time, warm ischemic time, estimated blood loss, complications, histology outcomes, and margin status were comparable. Pathology of 6 cystic tumors came back benign (21.4%). In solid tumors, 6 intraoperative bleeding require transfusion, 1 ureteral damage, and 3 postoperative urinary fistulas were observed. In cystic tumors, conversion to radical nephrectomy happened in one case, because of sticky fat and the risk of cyst rupture. In two cases, postoperative bleeding was treated with embolism. The longest follow-up was 113 months. In cystic group, 1 recurrence or metastasis was observed, while in solid group, 14 cases were observed.

conclusionRAPN can be safely performed to treat large (T2) cystic renal-cell carcinoma. Patients with cystic renal-cell carcinoma exhibited favorable renal function recovery after robot-assisted partial nephrectomy (RAPN), which maximally preserved normal renal tissue and its function. Further studies are needed to better understand the role of RAPN for these challenging cases.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNephrectomyRobotic Surgical ProceduresAdultAgedFeasibility StudiesFemaleHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesTreatment OutcomeTumor BurdenCystic renal-cell carcinomaNephron sparing surgeryPartial nephrectomyRobotic surgery

Identifiers

PMID40542967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.